Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL)
A multitude of new agents for the treatment of hematologic malignancies has been introduced over the past decade. Hematologists, infectious disease specialists, stem cell transplant experts, pulmonologists and radiologists have met within the framework of the European Conference on Infections in Leukemia (ECIL) to provide a critical state-of-the-art on infectious complications associated with immunotherapeutic and molecular targeted agents used in clinical routine. For brentuximab vedotin, blinatumomab, CTLA4- and PD-1/PD-L1-inhibitors as well as for ibrutinib, idelalisib, HDAC inhibitors, mTOR inhibitors, ruxolitinib, and venetoclax, a detailed review of data available until August 2018 has been conducted, and specific recommendations for prophylaxis, diagnostic and differential diagnostic procedures as well as for clinical management have been developed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Leukemia - 33(2019), 4 vom: 30. Apr., Seite 844-862 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Maschmeyer, Georg [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 09.08.2019 Date Revised 20.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41375-019-0388-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM293277974 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM293277974 | ||
| 003 | DE-627 | ||
| 005 | 20231225074952.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41375-019-0388-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0977.xml |
| 035 | |a (DE-627)NLM293277974 | ||
| 035 | |a (NLM)30700842 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Maschmeyer, Georg |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL) |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.08.2019 | ||
| 500 | |a Date Revised 20.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a A multitude of new agents for the treatment of hematologic malignancies has been introduced over the past decade. Hematologists, infectious disease specialists, stem cell transplant experts, pulmonologists and radiologists have met within the framework of the European Conference on Infections in Leukemia (ECIL) to provide a critical state-of-the-art on infectious complications associated with immunotherapeutic and molecular targeted agents used in clinical routine. For brentuximab vedotin, blinatumomab, CTLA4- and PD-1/PD-L1-inhibitors as well as for ibrutinib, idelalisib, HDAC inhibitors, mTOR inhibitors, ruxolitinib, and venetoclax, a detailed review of data available until August 2018 has been conducted, and specific recommendations for prophylaxis, diagnostic and differential diagnostic procedures as well as for clinical management have been developed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 700 | 1 | |a De Greef, Julien |e verfasserin |4 aut | |
| 700 | 1 | |a Mellinghoff, Sibylle C |e verfasserin |4 aut | |
| 700 | 1 | |a Nosari, Annamaria |e verfasserin |4 aut | |
| 700 | 1 | |a Thiebaut-Bertrand, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Bergeron, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Franquet, Tomas |e verfasserin |4 aut | |
| 700 | 1 | |a Blijlevens, Nicole M A |e verfasserin |4 aut | |
| 700 | 1 | |a Maertens, Johan A |e verfasserin |4 aut | |
| 700 | 0 | |a European Conference on Infections in Leukemia (ECIL) |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia |d 1989 |g 33(2019), 4 vom: 30. Apr., Seite 844-862 |w (DE-627)NLM012593788 |x 1476-5551 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2019 |g number:4 |g day:30 |g month:04 |g pages:844-862 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41375-019-0388-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2019 |e 4 |b 30 |c 04 |h 844-862 | ||